CBIH seeks a role in renewed DEA marijuana rescheduling hearing

By AI, Created 9:57 AM UTC, May 20, 2026, /AGP/ – Cannabis Bioscience International Holdings says it has filed a new notice to participate in the DEA’s renewed federal hearing on moving marijuana from Schedule I to Schedule III. The company says its focus is research, medicine, regulation and public health, as the debate over rescheduling continues to shape science, banking and investment access.

Why it matters: - The DEA rescheduling fight could change how marijuana is regulated, studied and financed in the U.S. - CBIH says the outcome affects not just cannabis businesses, but broader scientific research, medicine, banking and public trust. - A move from Schedule I to Schedule III would signal a less restrictive federal framework, even if controls remain in place.

What happened: - Cannabis Bioscience International Holdings said May 4, 2026, that it submitted a new Notice of Intention to Participate in the federal administrative hearing on marijuana rescheduling. - The hearing concerns a proposed transfer of marijuana from Schedule I to Schedule III under the Controlled Substances Act. - The Houston-based public company trades on the OTC Markets under the ticker CBIH. - CBIH previously took part in the administrative process tied to the proposed rulemaking. - The DEA renewed the proceedings, prompting CBIH to seek participation again.

The details: - CBIH says it wants to bring a perspective centered on research, medicine, regulation and public health. - The company says its position is backed by 25 completed patent assets for cannabinoid-based medical formulations. - Those patent assets cover neurological, psychiatric, oncological, metabolic, musculoskeletal, gastrointestinal, microbiome-related and other therapeutic areas. - Rosangel Andrades, MD, CBIH R&D Director, said stigma around marijuana policy affects banks, investors, researchers and clinical development. - Dante Picazo, CBIH chief executive officer, said rescheduling should create a clearer, more scientific and more organized framework, not eliminate controls. - CBIH said experienced voices with legal, business, public communication and human perspectives can help shape the broader discussion around stigma and public understanding.

Between the lines: - CBIH is positioning itself as more than a cannabis operator and as a participant in the policy and research debate. - The company is using its patent portfolio to argue that its input is grounded in scientific work, not just industry advocacy. - The emphasis on stigma suggests the company wants the hearing to address access to capital and research barriers as much as drug scheduling itself.

What’s next: - The DEA hearing process will continue as the agency considers whether marijuana should move to Schedule III. - CBIH’s notice gives the company a path to present its views in the federal proceeding. - The company flagged the filing as forward-looking and said outcomes could change based on risks, uncertainties and assumptions. - CBIH directed investors to its OTC Markets filings for more risk details and provided social media links in the release, including Instagram, TikTok and X.